leisure time -WSS

leisure time

author：hotspot 2025-09-28 21:06:17 - browse：15546

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Would Medicare drug price negotiations stall in a shutdown?

hotspot

WSS

Adopting new red light myopia treatments may be short

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

340B reform proposal comes out of Senate working group

340B reform proposal comes out of Senate working group

Adopting new red light myopia treatments may be short

focus

leisure time

leisure time

Drug repurposing or repositioning? The language matters

Top private equity targets in 2023: cardiology, clinical trials, lasers

23andMe had bad news about my health. I wish a person had delivered it

A single Democrat is willing to weaken Medicare negotiation power

Cancer drug shortages should be causing more outrage

Updated Covid vaccine has 54% effectiveness, new study suggests

Cancer drug shortages should be causing more outrage

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Heart attack and stroke risk calculators need revising

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

Updated Covid vaccine has 54% effectiveness, new study suggests

STAT Virtual Event: How to Increase Diversity in Clinical Trials

340B reform proposal comes out of Senate working group

Covid vaccines: Private market messier than government rollout

Health tech startups drop sharply from 2021 highs

Biogen shutters digital health group, ends Apple study, in cost cutting move

hotspot

Wikipedia

entertainment

hotspot